Skip to main content
padlock icon - secure page this page is secure

Nanocarriers Mediated Topical Drug Delivery for Psoriasis Treatment

Buy Article:

$68.00 + tax (Refund Policy)

Background: Psoriasis is a chronic autoimmune inflammatory skin disease affecting 2 to 3% of people worldwide. Topical therapy as first option in the management of psoriasis is an attractive strategy by delivering drugs efficiently into target sites of disease, minimizing systemic side effects of drugs and ensuring high patient compliance. However, the delivery of antipsoriatic agents via conventional topical formulations is limited due to their poor percutaneous penetration and targeting into deeper layers of the skin.

Method: In this review, an overview of skin structure and psoriatic skin as well as different approaches used for the treatment are provided. We discussed the topical nanocarriers including solid lipid nanoparticles, nanostructured lipid carriers, liposomes, niosomes, ethosomes, transfersomes, dendrimers and micelles used to deliver antipsoriatic drugs. We also summarized the 2011 onward research studies dealing with the application of nanocarriers for psoriasis treatment.

Result: In the last decades, numerous types of nanocarriers have been widely investigated as a novel delivery approach to reach effective antipsoriatic drug concentrations. These nanocarriers can enhance the therapeutic efficacy and minimize the toxicity of the drugs by lowering the dose. They also improve drug localization in the skin and achieve site-specific drug targeting. But, most of the available studies have lack of clinical outcome in psoriasis and required more focus on the clinical evaluation.

Conclusion: Nanocarriers could enhance deposition of antipsoriatic drugs in targeted sites of the skin. Nevertheless, still there is a need to develop more effective simulated models that provide realistic model for psoriasis.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Nanocarrier; anti-psoriatic drug; psoriasis; skin delivery; skin targeting; topical delivery

Document Type: Research Article

Publication date: May 1, 2017

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more